Table of Contents
ISRN Neurology
Volume 2011 (2011), Article ID 618624, 6 pages
http://dx.doi.org/10.5402/2011/618624
Research Article

Safety and Efficacy of Thrombolytic Therapy Using rt-PA (Alteplase) in Acute Ischemic Stroke

1Department of Pharmacy Practice, KMCH College of Pharmacy, Kovai Estate, Kalapatti Road, Coimbatore, Tamilnadu 48, India
2Department of Neurology, Kovai Medical Center and Hospital, Coimbatore, Tamilnadu 44, India
3Department of Pharmacy, Madurai Medical College, Madurai, Tamilnadu 20, India

Received 4 August 2011; Accepted 20 September 2011

Academic Editor: M. Xue

Copyright © 2011 Palanisamy Sivanandy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. S. Smith, S. L. Hauser, and J. D. Easton, “Cerebrovascular diseases,” in Harrison's Principles of Internal Medicine, E. Braunwald, Ed., p. 2369, McGraw-Hill, New York, NY, USA, 15th edition, 2001. View at Google Scholar
  2. J. L. Zehnder, “Drugs used in disorder of coagulation,” in Basic and Clinical Pharmacology, B. G. Katzung, Ed., pp. 552–553, McGraw-Hill, New York, NY, USA, 10th edition, 2007. View at Google Scholar
  3. W. S. Smith, J. D. English, and S. D. Johnson, “Cerebrovascular disease,” in Harrison's Principles of Internal Medicine, D. Braunwald, Ed., p. 2513, McGraw-Hill, New York, NY, USA, 17th edition, 2008. View at Google Scholar
  4. G. Micieli, S. Marcheselli, and P. A. Tosi, “Safety and efficacy of alteplase in the treatment of acute ischemic stroke,” Vascular Health and Risk Management, vol. 5, pp. 397–409, 2009. View at Google Scholar · View at Scopus
  5. C. F. Lacy, L. L. Armstrong, M. P. Goldman, and L. L. Lance, “Alteplase,” in Drug Information Handbook, C. F. Lacy, Ed., pp. 75–77, Lexicomp, Hudson, Ohio, USA, 19th edition, 2009. View at Google Scholar
  6. M. D. Hill and A. M. Buchan, “Thrombolysis for acute ischemic stroke: results of the Canadian alteplase for stroke effectiveness study,” Canadian Medical Association Journal, vol. 172, no. 10, pp. 1307–1312, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. L. Saver, “Thrombolytic therapy in stroke,” Emedicine, vol. 9, pp. 1–21, 2010. View at Google Scholar
  8. E. Meseguer, M. Mazighi, J. Labreuche, C. Arnaiz, L. Cabrejo, and T. Slaoui, “Outcomes of intravenous recombinant tissue plasminogen activator according to gender,” Stroke, vol. 40, pp. 2104–2110, 2009. View at Google Scholar
  9. N. K. Mishra, N. Ahmed, G. Andersen et al., “Thrombolysis in very elderly people: controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive,” BMJ, vol. 341, no. 7783, article c6046, 2010. View at Publisher · View at Google Scholar
  10. G. W. Albers, V. E. Bates, W. M. Clark, R. Bell, P. Verro, and S. A. Hamilton, “Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reverse stroke (STARS) study,” Journal of the American Medical Association, vol. 283, no. 9, pp. 1145–1150, 2000. View at Google Scholar · View at Scopus
  11. M. Ground, C. Stenzel, and S. Schumullling, “Early intravenous thrombolysis for acute ischemic stroke in a community-based approach,” Stroke, vol. 29, pp. 1544–1549, 1998. View at Publisher · View at Google Scholar
  12. N. Wahlgren, N. Ahmed, A. Davalos et al., “Thrombolysis with alteplase 3–4.5 hours after acute ischemic stroke (SITS—ISTR): an observational study,” The Lancet Neurology, vol. 372, no. 9646, pp. 1303–1309, 2008; 08:. View at Publisher · View at Google Scholar · View at PubMed
  13. M. D. Hill, F. L. Silver, P. C. Austin, and J. V. Tu, “Rate of stroke recurrence in patients with primary intracerebral hemorrhage,” Stroke, vol. 31, no. 1, pp. 123–127, 2000. View at Google Scholar · View at Scopus